Loading...
Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
AIMS: There is a controversy as to the relative efficacy of (177)Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether (177)L...
Na minha lista:
| Udgivet i: | Eur J Nucl Med Mol Imaging |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Springer Berlin Heidelberg
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5787223/ https://ncbi.nlm.nih.gov/pubmed/29247284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3895-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|